Alembic Pharmaceuticals Limited — Investor Meet, 11-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Alembic Pharma's Q1 FY26 revenue rose 10% YoY to Rs. 1,711 Cr, with net profit up 15% to Rs. 154 Cr. Gross margin improved to 76.2%. India business grew 5% to Rs. 599 Cr, with management working on execution and UCPMP alignment to achieve double-digit growth within months. International business saw RoW up 21% and US up 13% driven by volume and new launches. API revenue remained flat due to pricing pressure. The company expects US business to grow 10-15% this year with continued new product introductions. Gross debt stood at Rs. 1,185 Cr.